Literature DB >> 17209147

Prevalence of HIV infection in a general psychiatric outpatient population.

John L Beyer1, Laura Taylor, Kenneth R Gersing, K Ranga R Krishnan.   

Abstract

The prevalence of human immunodeficiency virus (HIV) infection in the general psychiatric population is unknown. The authors conducted a retrospective review of all patients evaluated through the psychiatric outpatient clinics at Duke University Medical Center from 2001 to 2004 in order to determine the prevalence of comorbid HIV infection and mental illness. HIV infection was present in 1.2% of the psychiatric outpatients, approximately four times the occurrence of HIV infection in the general adult population of the United States. The major psychiatric diagnostic categories with a high prevalence of HIV infection were substance abuse disorders (5%), personality disorders (3.1%), bipolar disorders (2.6%), and posttraumatic stress disorder (2.1%).

Entities:  

Mesh:

Year:  2007        PMID: 17209147     DOI: 10.1176/appi.psy.48.1.31

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  24 in total

1.  HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence.

Authors:  David J Moore; Carolina Posada; Mili Parikh; Miguel Arce; Florin Vaida; Patricia K Riggs; Ben Gouaux; Ronald J Ellis; Scott L Letendre; Igor Grant; J Hampton Atkinson
Journal:  AIDS Behav       Date:  2012-11

2.  Use of Medicaid data to explore community characteristics associated with HIV prevalence among beneficiaries with schizophrenia.

Authors:  James Walkup; Ayse Akincigil; Donald R Hoover; Michele J Siegel; Shahla Amin; Stephen Crystal
Journal:  Public Health Rep       Date:  2011 Sep-Oct       Impact factor: 2.792

3.  Screening and assessing violence and mental health disorders in a cohort of inner city HIV-positive youth between 1998-2006.

Authors:  Jaime Martinez; Sybil G Hosek; Russell A Carleton
Journal:  AIDS Patient Care STDS       Date:  2009-06       Impact factor: 5.078

4.  Gender, HIV status, and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Mariana Lopes; Mark Olfson; Judith Rabkin; Deborah S Hasin; Analucía A Alegría; Keng-Han Lin; Bridget F Grant; Carlos Blanco
Journal:  J Clin Psychiatry       Date:  2011-10-18       Impact factor: 4.384

5.  Substance use disorders and comorbid Axis I and II psychiatric disorders among young psychiatric patients: findings from a large electronic health records database.

Authors:  Li-Tzy Wu; Ken Gersing; Bruce Burchett; George E Woody; Dan G Blazer
Journal:  J Psychiatr Res       Date:  2011-07-13       Impact factor: 4.791

6.  Approaches to identifying appropriate medication adherence assessments for HIV infected individuals with comorbid bipolar disorder.

Authors:  Jayraan Badiee; Patricia K Riggs; Alexandra S Rooney; Florin Vaida; Igor Grant; J Hampton Atkinson; David J Moore
Journal:  AIDS Patient Care STDS       Date:  2012-06-11       Impact factor: 5.078

7.  CDC recommendations for opt-out testing and reactions to unanticipated HIV diagnoses.

Authors:  Carol L Galletly; Steven D Pinkerton; Andrew E Petroll
Journal:  AIDS Patient Care STDS       Date:  2008-03       Impact factor: 5.078

Review 8.  Management of common psychiatric conditions in the HIV-positive population.

Authors:  Kelly Brogan; Joseph Lux
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

9.  HIV risk behavior among patients with co-occurring bipolar and substance use disorders: associations with mania and drug abuse.

Authors:  Christina S Meade; Fiona S Graff; Margaret L Griffin; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2007-09-11       Impact factor: 4.492

10.  Utilization of primary care by veterans with psychiatric illness in the National Department of Veterans Affairs Health Care System.

Authors:  Lydia A Chwastiak; Robert A Rosenheck; Lewis E Kazis
Journal:  J Gen Intern Med       Date:  2008-09-16       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.